Vaccine value profile for norovirus

dc.contributor.authorArmah, G.
dc.contributor.authorVinjé, J.
dc.contributor.authorLopman, B.A.
dc.contributor.authoret al.
dc.date.accessioned2023-11-03T16:52:07Z
dc.date.available2023-11-03T16:52:07Z
dc.date.issued2023
dc.descriptionResearch Articleen_US
dc.description.abstractNorovirus is attributed to nearly 1 out of every 5 episodes of diarrheal disease globally and is estimated to cause approximately 200,000 deaths annually worldwide, with 70,000 or more among children in devel oping countries. Noroviruses remain a leading cause of sporadic disease and outbreaks of acute gastroen teritis even in industrialized settings, highlighting that improved hygiene and sanitation alone may not be fully effective in controlling norovirus. Strengths in global progress towards a Norovirus vaccine include a diverse though not deep pipeline which includes multiple approaches, including some with proven technology platforms (e.g., VLP-based HPV vaccines). However, several gaps in knowledge persist, including a fulsome mechanistic understanding of how the virus attaches to human host cells, internal izes, and induces disease.en_US
dc.identifier.otherhttps://doi.org/10.1016/j.vaccine.2023.03.034
dc.identifier.urihttp://ugspace.ug.edu.gh:8080/handle/123456789/40665
dc.language.isoenen_US
dc.publisherVaccineen_US
dc.subjectVaccinesen_US
dc.subjectGlobal Healthen_US
dc.titleVaccine value profile for norovirusen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
1-s2.0-S0264410X23003183-main.pdf
Size:
804.89 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: